Lava Therapeutics B.V.
Oxana Polyakova is an accomplished scientific leader with extensive experience in the biotechnology sector. As the Chief Scientific Officer at LAVA Therapeutics N.V., Polyakova spearheads scientific initiatives. Previously, Polyakova co-founded Adaptate Biotherapeutics and served as Head of Discovery, contributing significantly to the company's innovative research. Prior roles include serving as the Protein and Molecular Group Lead at GammaDelta Therapeutics and Biology Group Leader at Kesios Therapeutics, where Polyakova focused on advancing biological research and development.
This person is not in any teams
This person is not in any offices
Lava Therapeutics B.V.
Lava Therapeutics is focused on applying its expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy.